Vivera Pharmaceuticals’ Chief Medical Officer Dr. Stephen J. McColgan Appointed Clinical Instructor At University of California, Riverside, School of Medicine
Newport Beach, California–(Newsfile Corp. – August 14, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management is pleased to announce that
Vivera Pharmaceuticals Welcomes Daniel Baldwin to Ambassador Board
Newport Beach, California–(Newsfile Corp. – August 8, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management is pleased to welcome Mr.
Vivera Pharmaceuticals Welcomes Sally Pera To Advisory Board
Newport Beach, California–(Newsfile Corp. – July 29, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management is pleased to announce the
Vivera Pharmaceuticals Names Brad Townend Executive Creative Director
Newport Beach, California–(Newsfile Corp. – July 25, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the appointment of
Vivera Pharmaceuticals Committed To Research and Development To Help Fight The Opioid Crisis
Newport Beach, California–(Newsfile Corp. – July 18, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces its continued commitment
Vivera Pharmaceuticals Names Dr. Mehdi Hatamian Senior Scientific Advisor
Newport Beach, California–(Newsfile Corp. – July 11, 2019) – Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the appointment of
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
